Chardan starts coverage of MannKind stock with a USD 10.00 target

Published on 10/20/2026 at 20:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 109.37 million versus USD 108.92 million consensus. MannKind stock costs EUR 2.78 on October 20, 2026 at 8:13 p.m. CEST.

Analyst target and revenue

Chardan initiated coverage with a USD 10.00 target and Buy rating on October 19, 2026.
MannKind reported second-quarter 2026 revenue of USD 109.37 million against USD 108.92 million consensus.
MannKind stock costs EUR 2.78 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST.
The Nasdaq quote was USD 3.12 with a USD 2.23 to USD 6.51 52-week range on October 20, 2026.

MNKD, US56400P7069, Illustration mit AI erstellt.

MannKind (ISIN US56400P7069) received a new Buy rating and a USD 10.00 price target when Chardan initiated coverage on October 19, 2026, according to Investing.com. MannKind was trading at EUR 2.78 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST.

Revenue cleared consensus

The latest reported operating figure came from the second quarter ended June 30, 2026. MannKind generated USD 109.37 million in revenue against USD 108.92 million consensus, while adjusted loss per share was USD 0.01, according to SEPT Investing. Revenue increased 43.00 percent from the prior year, giving the analyst call a commercial metric to assess alongside the pipeline.

Nasdaq range sets the frame

The Nasdaq quotation was USD 3.12 on October 20, 2026 at 2:19 p.m. ET. MannKind's market capitalization was USD 1.0 billion, its trailing P/E was minus 22.77, and its 52-week range was USD 2.23 to USD 6.51 on the same date.

Valuation and dated events

Chardan's target is expressed in USD, the currency of MannKind's primary Nasdaq listing, and stands apart from the euro quotation used for German investors. The company identifies itself as a biopharmaceutical business focused on cardiometabolic and orphan lung diseases, including Afrezza, FUROSCIX and Tyvaso DPI, on its investor-relations page.

MannKind's investor-relations calendar listed participation in the Chardan Healthcare Conference on October 14, 2026. It also listed October 9, 2026 data from the Heart Failure Society of America meeting and the September 9, 2026 licensing and collaboration agreement with Rose Pharma.

Stock position after coverage

The current euro quotation sits below the Nasdaq quotation because the two figures use different currencies and venues. The Nasdaq price and market value provide the trading context, while the second-quarter revenue figure and Chardan's USD 10.00 target are the two dated benchmarks most directly tied to the latest coverage.

Trading context for MannKind

MannKind was trading at EUR 2.78 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST. The Nasdaq quote stood at USD 3.12 on October 20, 2026 at 2:19 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of MannKind stock.